Clinical Trials

AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA

EudraCT / EU CT No
2024-514139-50-00
Protocol No
C1071006

Trial information

Medical condition
MM
Trial phase
Phase 3
Sponsor
Pfizer
Start date
02/11/2023
End date
01/04/2028
Main objective
To evaluate the efficacy and safety of elranatamab+daratumumab+lenalidomide versus daratumumab+lenalidomide+dexamethasone in transplant-ineligible newly diagnosed multiple myeloma.

Locations and Contact points